Author

J. S. Schoeniger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:bacteria (other)· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1 Research Focus:variant effect prediction· 1 Organism:virus· 1

Frequent Co-Authors

A. Lahiri· 1 shared A. M. Phillips· 1 shared B. A. Adler· 1 shared B. F. Cress· 1 shared B. Harmon· 1 shared C. E. Thatcher· 1 shared C. M. Courtney· 1 shared C. M. Mageeney· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Lahiri

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genome-wide Characterization of Diverse Bacteriophages Enabled by RNA-Binding CRISPRi

B. A. Adler, M. J. Al-Shimary, J. R. Patel, E. Ambruster, D. Colognori, E. J. Charles, K. V. Miller, A. Lahiri, M. Trinidad, R. Boger, J. Nomburg, S. Beurnier, M. L. Cui, R. Barrangou, V. K. Mutalik, , B. F. Cress

The paper develops a CRISPRi-ART system to knock down protein expression in diverse bacteriophages and identifies essential genes, including many with unknown functions.

bioRxiv · Sep 18, 2023 · PreprintMicrobiology

Development of Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies

M. A. Stefan, Y. K. Light, J. L. Schwedler, P. R. McIlroy, C. M. Courtney, E. A. Saada, C. E. Thatcher, A. M. Phillips, F. A. Bourguet, C. M. Mageeney, S. A. McCloy, N. M. Collette, O. A. Negrete, J. S. Schoeniger, D. R. Weilhammer, B. Harmon

This paper identifies and characterizes potent SARS-CoV-2 neutralizing nanobodies that block viral entry and show efficacy in vivo.

mAbs · Aug 4, 2021Peer-reviewedImmunology